Balchem: 3 Key Takeaways for Long-Term Investors
Key Points
Third-quarter net sales rose 8.6% year over year to $291 million.
Human nutrition and health segment sales increased 8.1% to $188 million.
Animal nutrition and health operating earnings rose 82.8% to $6.8 million.
- 10 stocks we like better than Balchem ›
On its third quarter of 2026 earnings call, held on Oct. 23, 2026, Balchem (NASDAQ:BCPC) announced record quarterly consolidated sales of $291 million. The company continues to expand profit margins by shifting toward high-value nutrient technologies. Consistent cash generation supports reinvestment in innovation while keeping debt low. Three takeaways from the call stand out.
1. Clinical Trials Expand Specialty Ingredients Into Adult Health
Balchem is expanding its science-backed ingredients, including VitaCholine brand choline and K2VITAL DELTA brand vitamin K2, from infant nutrition into adult cognitive and cardiovascular markets. Clinical validation builds pricing power and customer trust in high-margin specialty markets.
The findings provide encouraging new evidence that may support the role of VitaCholine in lifelong brain health and further strengthen the scientific foundation of choline in healthy aging and cognition.
-- Theodore L. Harris, Chairman, President, and Chief Executive Officer
2. Proprietary Tech Drives Adoption in Animal Nutrition
Farmer adoption of encapsulated nutrient technology improves herd efficiency and protects sales from broader market swings. International expansion and new product launches further extend this advantage.
Market penetration is still one where even if the market were not to grow, we can still drive growth through penetration and adoption of our technologies
-- Carl Martin Bengtsson, Chief Financial Officer
3. High-Margin Product Mix Fuels Segment Profitability
Faster sales growth in premium human and animal nutrients relative to standard products creates a natural margin boost. Passing through higher input costs protects cash flow while product mix expands profitability.
So there are tailwinds within both of those segments. And, obviously, with our specialty products segment having grown nicely, being very high margin as well for us as a business, it just supports a nice tailwind for us.
-- Carl Martin Bengtsson, Chief Financial Officer
Looking Ahead
Fourth-quarter operations face typical seasonal slowdowns, but demand trends stay intact. Proprietary technology and a credit facility position Balchem to expand capacity, while leadership prioritizes supply chain security.
As we look ahead to the fourth quarter, we are optimistic about the outlook.
-- Carl Martin Bengtsson, Chief Financial Officer
Organic sales gains and steady capital allocation reinforce long-term stability across shifting economic cycles.
The third quarter marked our 29th consecutive quarter of year over year growth in adjusted EBITDA. That level of consistency across a wide range of market conditions reflects the strength of our unique portfolio, the resilience of our business model, and the dedication of our team.
-- Theodore L. Harris, Chairman, President, and Chief Executive Officer
Should you buy stock in Balchem right now?
Before you buy stock in Balchem, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Balchem wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $361,596!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,303,935!*
Now, it’s worth noting Stock Advisor’s total average return is 910% — a market-crushing outperformance compared to 211% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of October 23, 2026.
The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
